Figure 12K depicted six immune checkpoints highly expressed in the high-risk group, including CD276, CD86, HAVCR2, LAIR1, TNFSF9, and TNFRSF14, which collectively impeded antitumor immune responses. Figure 12L depicted the six drugs with low IC50 values in the high-risk group, suggesting that the high-risk group was more sensitive to these drugs. Overall, the findings suggested that TCs with elevated levels of FN1 might play a key role in immunotherapy resistance and could serve as a compelling biomarker in predicting survival time in patients with ovarian tumors. The gene discussed is CD276; the disease is ovarian neoplasm.